Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01389206 · ClinicalTrials.gov registry record
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
A clinical trial, sponsored by Actelion.
- Completed
- Registry status
- 797
- Enrollment target
NCT01389206: Completed study, sponsored by Actelion.
NCT01389206 is a clinical trial that has completed, run by Actelion. The registered enrollment target is 797 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01389206 has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 797 participants
- Enrollment target
Study Summary
Knowledge Translation Program for the guidelines and evidence-based management of PAH patients
Primary Outcome
Proportion of patients achieving guideline-recommended treatment
Interventions
- DRUG observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 797 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2018-04-10 |
What the finished NCT01389206 record still lists
NCT01389206 is an observational study that tracks outcomes without assigning an intervention. The registered 797 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi is the first listed.
NCT01389206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01389206 about?
NCT01389206 is a clinical study titled "Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program". Knowledge Translation Program for the guidelines and evidence-based management of PAH patients
What is the current status of trial NCT01389206?
This trial is currently completed. The enrollment target is 797 participants. The study started on 2011-06-01. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT01389206?
The interventions under investigation include: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi (DRUG).
Who is sponsoring clinical trial NCT01389206?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI